Petvivo Holdings, Inc. Hires Wes Hayne As Chief Executive Officer

MINNEAPOLIS, MINNESOTA, USA, July 20, 2017 / — Petvivo Holdings, Inc. (OTCPINK: PETV) ( is pleased to announce its recent hire of Wesley Hayne, who will join the Petvivo team as Chief Executive Officer (CEO). Mr. Hayne will be taking over the position immediately. His immediate efforts will be to concentrate on the organizational and financial strategies of the company.

“I was attracted to the company by the potential of a regenerative biomaterial that may be used in a number of tissue applications; my interest was further enhanced when I was made aware of the biomaterial’s impact in the treatment of osteoarthritis. It was easy to accept the position once I had a complete understanding of how life changing this product can be for humans in addition to animals. The sustainability of the product once injected into dogs and horses is incredible. The “Particles”, in testing to date, have proven safe, with no side effects from the various applications.”

“We are very pleased to have Wes join the PetVivo team,” noted John Lai, who will now serve as the Company’s President. “Wes and I first worked together more than twenty-five years ago. Wes has an excellent track record of leading companies to commercial success and I am very confident he can do the same for PetVivo.”

Wes is an accomplished professional having served as CEO or President of several companies in start-up and/or high growth stages. He has extensive experience in strategic planning with an emphasis on finance, business development and sales/marketing. He further has hands on expertise in investment banking, structuring capital funding, divestures and mergers and acquisitions. Wes also has an extensive history in identifying business opportunities for expansion, motivating/managing sales forces, and providing decisive resolution to corporate problems.

“It is my intention to see this innovative technology penetrate numerous medical sectors, not only as a company introducing products to market itself, but also as a company that cultivates domestic and foreign licensing opportunities with strategic partners. In my opinion, the entire world is looking for this kind of advancement for treating many debilitating afflictions like osteoarthritis. To date there has been no real treatment for osteoarthritis, yet with age nearly all dogs, horses and humans are faced with it.”

About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
John Lai
PetVivo Holdings, Inc.
Phone: 612-296-7305

John Lai
Petvivo Holdings, Inc.
email us here

Source: EIN Presswire

LiVe Well Lanes Visited 8 Million Times Since Opening in Utah Grocery Stores

Partnership helping Utahns live healthier lives

SALT LAKE CITY, UTAH, USA, July 20, 2017 / — LiVe Well Lanes have exceeded 8 million visits in their first three months. LiVe Well Lanes are located at Associated Foods Stores retailers throughout Utah and contain healthy options for quick snacks.

The LiVe Well checkout lanes were created in January 2017 as a partnership between Intermountain Healthcare, Associated Food Stores, the Utah Department of Health and Utah’s local health departments. The lanes are in 43 Associated Food Stores locations, which includes Macey’s, Dan’s, Dick’s Market, and Fresh Market.

"The LiVe Well Lane allows you to choose a snack that offers a nutritional benefit," says Joy Musselman, a dietitian and clinical nutrition manager at Intermountain. "Items offered include fruits, vegetables, nuts, calcium-rich dairy, and whole grains — all foods we typically don't get enough of in our diets. Using the LiVe Well Lane, you can easily choose a snack that will help fulfill something that might be deficient in your diet."

The LiVe Well Lanes have one specific area among the checkout lines in the stores. Shoppers chose the LiVe Well Lanes 25 percent of the time. Healthy items sales have increased 49 percent during the first three months, which translated into about 60,000 healthy items sold.

"We're thrilled with the early results as we work together to make it easier for customers to find healthier choices for their families," says Neal Berube, CEO of Associated Food Stores and a member of Intermountain's Board of Trustees. "Associated Food Stores appreciates the opportunity to participate with Intermountain Healthcare in serving the community. As we take this journey we understand people are seeking better options in meeting their nutrition and fitness goals."

“These numbers reflect that both consumers and retailers benefit from the convenience of healthier options in checkout lanes,” says Jess Church, public health dietitian at Utah Department of Health. “We’re really proud of cross-sector partnerships like this one that make Utahns’ health a priority in our communities.”

The growth will likely continue as additional stores have the opportunity to initiate the program.

Intermountain Healthcare is a Utah-based, not-for-profit system of 22 hospitals, 185 clinics, a Medical Group with some 1,500 employed physicians, a health plans division called SelectHealth, and other health services. Helping people live the healthiest lives possible, Intermountain is widely recognized as a leader in clinical quality improvement and in efficient healthcare delivery.

The mission of the Utah Department of Health is to protect the public's health through preventing avoidable illness, injury, disability and premature death, assuring access to affordable, quality health care, and promoting healthy lifestyles.

Daron Cowley
Intermountain Healthcare
email us here

Source: EIN Presswire

NeurAegis NA101 is neuroprotective in a mouse model of Traumatic Brain Injury (TBI)

A new study indicates that the selective calpain-2 inhibitor, NA101, prevents cell death and facilitates behavioral recovery when administered after TBI.

POMONA, CALIFORNIA, UNITED STATES, July 20, 2017 / — NeurAegis published the results of a series of experiments showing that NA101, the company’s lead selective calpain-2 inhibitor, is neuroprotective when injected after TBI. The article, “Protection against TBI-induced neuronal death with post-treatment with a selective calpain-2 inhibitor in mice” was published online in the Journal of Neurotrauma in June 2017 ahead of print. Click here to read more:
The study showed that calpain-1 was activated early in cortical areas surrounding the impact, within 0–8 h after TBI, while calpain-2 activation was delayed and was predominant during 8–72 h after TBI. Calpain-1 knockout enhanced cell death, while calpain-2 activity correlated with the extent of cell death, suggesting that calpain-1 activation suppresses while calpain-2 activation promotes cell death following TBI. Systemic injection(s) of a calpain-2 selective inhibitor, NA101, at 1 h or 4 h after TBI significantly reduced calpain-2 activity and cell death around the impact site, reduced the lesion volume, and promoted motor and learning function recovery after TBI. The results indicate that calpain-1 activity is neuroprotective, while calpain-2 activity is neurodegenerative after TBI, and that a selective calpain-2 inhibitor not only reduces TBI-induced cell death but also improves the recovery of neurological functions. “These results clearly demonstrate that a selective calpain-2 inhibitor has significant potential to be developed as a new therapeutic approach for limiting neuropathological damage after TBI and equivalent conditions, such as concussion and stroke” said Dr. Baudry, NeurAegis CEO. NeurAegis is now actively pursuing the preclinical development of new selective calpain-2 inhibitors through partnership with various companies.

About NeurAegis
NeurAegis ( has been founded to translate fundamental discoveries on the mechanisms of synaptic plasticity and neuronal survival/cell death into clinical applications. These discoveries are the results of over 30 years of research by the scientific co-founders, Michel Baudry, PhD, Dean of the Graduate College of Biomedical Sciences (Western University of Health Sciences, Pomona, CA), and graduate from Ecole Polytechnique, Paris, France (X68), and Xiaoning Bi, MD, PhD, Professor, COMP (Western University of Health Sciences, Pomona, CA), directed at understanding the roles of selective biochemical cascades in both synaptic plasticity and neuroprotection/neurodegeneration. NeurAegis has identified neuroprotection as a key focus for research and development, because of the high unmet needs and tremendous research potential in this therapeutic area. Much work has been conducted to identify the mechanisms underlying neuronal death and significant progress has been made over the last 10-20 years. Nevertheless, there is still no drug on the market that provides any significant degree of neuroprotection, especially within the crucial minutes to maximum of several hours following any brain insult that results in neuronal loss.
Contact information:
Michel Baudry, CEO, NeurAegis:

Michel Baudry
email us here

Source: EIN Presswire

Enterprise Learning! Conference Sponsors Embrace Innovation – Sponsors to Meet 125 Top Global Learning Organizations

ELC17 Conference Brochure

Catherine Upton, Enterprise Learning! Conference Chair

Eleven Sponsors & Partners Endorse ELC17; Representing Technology Innovation From AI, Cognitive Systems, Learning Ecosystems, Strategy Planning & Leadership

“From AI to personalized learning, solutions providers are key to the enterprise’s evolution. ELC17 partners with experts in learning ecosystems, engagement & big data; key resources for attendees.”

— Catherine Upton, Enterprise Learning! Conference Chair

SAN DIEGO, CA, USA, July 20, 2017 / — Elearning! Media Group, the leader in learning and workplace technology media, announced key partners and sponsors of the Enterprise Learning! Conference 2017 (ELC17). The event takes place August 29-30, 2017 in San Diego, CA and focuses on “Building the High-Performance Organization in the Age of Disruption.”

The Enterprise Learning! Conference 2017 hosts global thought leaders and executives from corporate enterprise, government agencies, higher education and non-profit organizations. Leaders share how to build the high-performance organizations in the age of digital disruption. ELC17 serves the robust $243 billion learning and workplace technology market expanding at 17% CAGR.

“From AI to personalized learning, solutions providers are central to the enterprise’s evolution,” reports Catherine Upton, conference chair, ELC17. Partners and sponsors are experts in learning ecosystems, engagement, personalization and data analytics. Attendees will meet and share with experts across all these practices. We welcome and thank eleven ELC sponsors and partners who make this event possible.”

ELC17 Sponsors & Partners

Advanced Distributive Learning Initiative
The Advanced Distributed Learning Initiative can only fulfill its mission by partnering with the Services, Defense agencies, and Federal agencies in collaboration with the private sector and academia.

Association of Talent Development of San Diego
The San Diego chapter of the Association of Talent Development (formerly ASTD) was chartered in 1947. Members represent financial and educational institutions, retailers, hospitals, high technology firms, manufacturing, government agencies, service industries, construction, tourism, publishing and airlines, as well as independent consultants and students.

Baker Communications Inc.
Since 1979, Baker Communications has trained over 50% of the Fortune 500 with a unique blend of award-winning sales training, acclaimed sales methodology and patented technology that produces sellers who typically outperform 98% of those people trained in traditional classroom environments. This unique approach combines learning reinforcement tools such as individual, manager and team coaching; learning-reinforcement gamification; 24×7 Sales Mastery On-Demand e-learning; and the ability to embed custom and standard online training inside most CRMs.

D2L is the software leader that makes the learning experience better. The company’s cloud-based platform is easier to use, more flexible, and smart. With Brightspace, companies can personalize the experience for every learner to deliver real results.

Elearning! Media Group
A 24-time award-winning media group, Elearning! Media Group serves the $243 billion enterprise learning &workplace technologies market.

Federal Government Distance Learning Association
FGDLA is a nonprofit association formed to promote the development and application of distance learning and to actively foster collaboration and understanding among those involved in leveraging technology in support of the education and training needs of the Federal government employee.

Future Workplace
Future Workplace is an HR executive network and research firm dedicated to the future of learning and working. Future Workplace operates the Future Workplace Network, a consortium of global companies who come together to anticipate and plan for disruptive changes in their companies, industries, and geographic markets.

getAbstract is a long-term solution to information overload. Our expert editorial team curates and summarizes the best business knowledge into 10-minute reads so that you can make better decisions in less time. With over 15,000 business book, article, video talk and economic report summaries, getAbstract is the world’s leading provider of summarized content. More than 10 million users – including 40% of Fortune 100 companies – use getAbstract to get the information they need to succeed.

IBM is a global technology and innovation company headquartered in Armonk, NY. Just completing its 22nd year of patent leadership, IBM Research has defined the future of information technology with more than 3,000 researchers in 12 labs located across six continents. Today, IBM is now emerging as a cognitive solutions and cloud platform company.

University of Phoenix
University of Phoenix is constantly innovating to help working adults move efficiently from education to careers in a rapidly changing world. Flexible schedules, relevant and engaging courses, and interactive learning can help students more effectively pursue career and personal aspirations while balancing their busy lives. University of Phoenix serves a diverse student population, offering associate, bachelor’s, master’s and doctoral degree programs from campuses and learning centers across the U.S. as well as online throughout the world.

Zappos Insights
Zappos Insights is a department within the Zappos Family of Companies created simply to help share the Zappos Culture with the world. Yep, that means YOU! We are humbled by the attention Zappos has received and all the questions we get about our unique culture and business.

How to Register

Meet these forward-thinking learning solutions providers at ELC17, August 29th- 30th in San Diego, CA. View the complete ELC17 conference program at:
Register today at:

About the Enterprise Learning! Conference 2017

ELC17 convenes over 125 award-winning learning professionals to share the best practices of high performance organizations, lessons learned, and future strategies. Invest 48 hours at ELC17 and discover how to engage teams, build a productive learning culture, measure impact and embrace the future digital enterprise. To sponsor ELC17, email or call 888-201-2841 x844.

Who Should Attend

Executives charged with driving enterprise performance via learning and workplace technologies, including HR, Talent, Development, Training, E-learning, Project Management, Education, Sales & Service should attend ELC17. Government, non-profit agencies and educational institution leaders are also in attendance to collaborate on the now and the next in learning. Attending this conference is an amazing opportunity to meet colleagues from across the globe. Registration is now open at:

About Elearning! Media Group
Elearning! Media Group is owned by B2B Media Group LLC. Elearning! Media Group consists of eleven media products including: Elearning! Magazine, Government Elearning! E-Magazine, e-mail newsletters, Alerts, Websites, Web seminars, the Enterprise Learning! Summit and Enterprise Learning! Conference. Elearning! Media Group serves the $243 billion learning & workplace technology market. Suppliers and practitioners can follow us: online at; on Twitter: @2elearning or #ELCE #EL17; via Facebook: Elearning! -Magazine or LinkedIn: Elearning! Magazine Network or Enterprise Learning! Conference.

Catherine Upton
B2B Media Co LLC
email us here

Source: EIN Presswire

One of Houston’s Fastest Growing MedSpas, DermaTouch RN, Moves to Expansive New Location

New location at 13725 Falba Road – Houston

Reception area of new DermaTouch RN facility

DermaTouch RN downstairs waiting area

Nestled in the Heart of Northwest Houston, the Fully Equipped Beauty and Wellness Center is Now the Complete Luxury Spa Retreat

We are really excited about this new space. It is a tranquil escape yet fully equipped facility for clients – whether they’re coming in for some BOTOX before vacation or complete aesthetic plan.”

— Renee Moschitto

HOUSTON, TEXAS, UNITED STATES, July 20, 2017 / — DermaTouch RN has moved into its new beauty and wellness center located less than a mile away from its previous location in Northwest Houston. Located at 13725 Falba Road, the recently renovated 6,000 square foot state-of-the-art facility now offers clients a complete luxury spa retreat and the latest aesthetic treatments available in the industry.
Over a year in the making, the beautiful new facility situated on a sprawling park-like estate is equipped with the latest technology and an experienced team of registered nurses and aestheticians. Together with consulting physician Scott Yarish, DermaTouch RN is strengthening its foothold as one of Houston’s premier MedSpas able to offer both short and long-term aesthetic and wellness programs.
The vision of Renee Moschitto, RN BSN, owner and founder of DermaTouch RN, the move and expanded accommodations enable staff to better meet the needs of clients and create a more complete wellness center – including educational sessions on cosmetic products and treatments, group social gatherings, Bioidentical hormone replacement and overall wellness therapies Q&A with wine and more.
“We are really excited about this new space. It is a tranquil escape yet fully equipped facility for clients, whether they’re coming in for a little BOTOX and body contouring before vacation or long-term aesthetic plans addressing multiple areas of concern,” said Moschitto, one of the top aesthetic injectors and Allergan educators in Texas.
“We are honored to treat several generations of family members in some cases and take great responsibility in doing so. We carefully assess performance and scientific outcomes on every new cosmetic product and treatment coming to market – selecting only the best for our clients,” added Moschitto.

Moschitto celebrated the 10th anniversary of DermaTouch RN this past year and attributes the success of her MedSpa to the experienced staff she hand-picks from within the industry, the technology in which she has invested for the center and the innovative treatments both trending and proving effective for clients.
Renee Moschitto is a registered nurse with over a decade of Aesthetic nursing experience. A facial anatomy expert, she serves as a National Trainer for Allergan, the global pharmaceutical company which produces Botox® and injectable fillers such the Juvéderm Voluma® family of products. Combining her nursing, biology and chemistry background, she left Memorial Hermann in 2006 to open DermaTouch RN. Today she is recognized as a model for responsible and innovative best practices in aesthetics – forming the Texas Association of Aesthetic Nurses Organization to ensure transparency, uniformity and quality of care.
To learn more about DermaTouch RN and the exciting new activities the facility is now able to offer go to or call 281.895.9090.

Cristy Hayes
Press Contact
email us here

Source: EIN Presswire

Asia Pacific Insomnia Market is Expecting a Sound Growth of CARG 5.1% During Forecast Period Of 2017-2023

Asia Pacific Insomnia Market

Asia Pacific Insomnia Market

Market Research Future published a half-cooked research report on Asia Pacific insomnia market, its Expecting a Sound Growth of CARG 5.1% During Forecast 2023

PUNE, MAHARASHTRA, INDIA, July 20, 2017 / — Asia Pacific Insomnia Market Research Report, By Types Of Therapy (Pharmacological Therapy And Non-Pharmacological Therapy), By Drug Formulation (Capsules, Tablet And Others), By Type Of Diseases (Poor Quality Of Sleep, Sleep Maintenance And Other) – Forecast Till 2023
Insomnia is being consider as one of the major problems in the developing countries. It is a sleep disorder associated with disturbance in sleep. As the exact cause is not found, there is no absolute treatment available, Asia Pacific insomnia market is driven mainly because of increasing insomnia patients. High incident of mental disorders, increasing workload and pressure, changing lifestyle and adoption of alcohol and tobacco also contributed in the growth of the market. Insomnia drugs has found its application in treatment of diseases like Parkinson’s, Alzheimer’s and cancer. Increasing prevalence of these diseases also contributed in the growth of the market. Lack of education about this disorder may hamper the growth of the market.

Get a sample report at .

Asia Pacific insomnia market has been segmented on the basis of types of therapy which comprises pharmacological therapy and non-pharmacological therapy. Pharmacological therapy is further segmented into benzodiazepines, non-benzodiazepines, melatonin receptor agonists and other. Non pharmacological treatment are further segmented into relaxation therapy, cognitive behavioral therapy, sleep hygiene education, stimulus control, paradoxical intention and other. By drug formulation they are segmented as capsules, tablet and others. On the basis of type of disease they are poor quality of sleep, sleep maintenance and other.
Majority of market is dominated by
• Takeda Pharmaceutical Company (Japan)
• Pfizer, Inc. (US)
• Eisai, Co. (Japan)
• Merck & Co Inc (US)
• Sanofi (France)
• GlaxoSmithKline Plc. (UK)
• Meda Consumer Healthcare Inc (US)
• Care Fusion Corporation (US)
• Pernix Therapeutics (US)
• Purdue Pharma L.P. (US)
• Dainippon Sumitomo (Japan)
• Johnson & Johnson (US)
• Astellas (UK)
• Neurim (Switzerland)
• Flynn Pharma (UK)
Lack of absolute treatment has provided a huge scope and opportunities for the development of the market. Major companies are working in the development for introduction of better treatment for insomnia.
Eisai, Co. is a Japanese pharmaceutical company concentrating in research and development of the new product. In Oct 2016, company has started Phase II clinical study for Lemborexant which is a dual orexin receptor antagonist for the treatment of patient suffering from sleep-wake rhythm disorder. E2006 is the major selling product of the company. In 2015, Eisai, Co. is worldwide collaborated with Purdue Pharma for development of Lemborexant.
Merck & Co Inc is one of the largest pharmaceutical company headquartered in US. Company has recently got approval for BELSOMRA for adult who have trouble falling asleep and staying asleep.
Takeda Pharmaceutical Company is a top 15 pharmaceutical company in the world and a largest pharmaceutical company in Japan and Asia. Takeda Pharmaceutical and Meiji announced a co-promotion agreement for ROZEREM for the treatment of insomnia.

Browse complete report at .

Pfizer, Inc. is a US headquartered pharmaceutical company. SONATA is one of the major product of this company. Company is focusing on the development of the new sleeping pills. Company has successfully completed the phase 4 study of Pristiq for the treatment of depressive disorders.
Dainippon Sumitomo a Japanese pharmaceutical company headquartered in Japan. In 2017, company has announced partnership with Bukwang for the development of market in Korea. In 2015, Dainippon Sumitomo and Hitachi has started a joint research on the development of the medicines for Parkinson's disease.

On regional basis, Japan accounts the largest share in the Asia Pacific insomnia market. 1 in every 5 people in japan is suffering from acute or chronic symptoms of insomnia. In Japan insomnia is the major problem than anxiety and depression. India and China are also contribute major share in the market. Approximately 5% of total India’s population is suffering from insomnia. This increasing number of people suffering from insomnia is the major driving factor for the market in Asia Pacific region.

Get a discount at .

The report for Asia Pacific insomnia market research report of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here

Source: EIN Presswire

Abdominal Surgical Robot Market Forecasts to Reach $15.8 Bn in 2023 from $2.7 Bn in 2016 – Phenominal Growth Expected

Orbis Research

Orbis Research

Orbis Research Present's New "Abdominal Surgical Robot Market Shares, Strategies, and Forecasts, Worldwide, 2017 to 2023" Report

DALLAS, TEXAS, UNITED STATES, July 20, 2017 / — Description

Orbis Research announces that it has published a new study Abdominal Surgical Robot Market Shares, Strategies, and Forecasts, Worldwide, 2017 to 2023. The study has 524 pages, 202 tables and figures.

Worldwide Abdominal Surgical Robot markets are expected to achieve significant growth as robots replace open surgery in treatment of abdominal disease conditions. Visualization of the surgical site is improving, giving surgeons better insight into the surgical site. The robots permit a more accurate and steadier cutting than is possible with open surgery.

Treatment via a robotic approach to abdominal surgery is useful for benign and malignant gynecologic conditions. Urologic and abdominal disease conditions are being treated increasingly with robotic surgery. Challenges still exist at a systems level. Implementation of a robotic program has a long learning curve. Resistance by surgeons on the team who are not adept at using the systems, quality of life, and financial challenges are being addressed in the industry. Challenges arise because of high capital expense, and organizational challenges continue to exist on an ongoing basis.

Get a PDF Sample of Abdominal Surgical Robot Market 2017-2023 Report at:

This is being addressed as more surgeons are trained and gain experience in the market. The world market for abdominal surgical robots is at $2.9 billion in 2017. The Robotic surgery equipment industry revenue is projected to increase to $12.9 billion by 2022. Robotic surgery equipment continues to comprise a fast-growing segment of the medical device industry. Demand for the less invasive procedure is high among patients and doctors. The number of procedures and disposable instruments increases.

Existing open surgery is set to be replaced by robotic-assisted surgery. Young surgeons have steady hands, but even the greatest surgeons have off days and they age. As this happens, the advantages of the robot are evident because the hand is steady every time with the robot.

During a robot assisted surgical procedure, the patient-side cart is positioned next to the operating table with the electromechanical arms arranged to provide access to the initial ports selected by the surgeon.

Technologies for abdominal robotic surgery applications has had growing adoption and commercialization. These technologies work in solving surgical approaches to many gynecology, urology, and general surgical issues. Robotic surgical procedures have reached a level of market acceptance that proves their value. Market saturation is a distance away, the industry is still in its infancy.

The technology available is becoming more sophisticated in order to overcome hurdles. The objectives of overcoming the limitations of fixed port access, limited dexterity, and limited visualization remain. The industry leader, the only company with a commercial footprint, within the robotic surgical market is Intuitive Surgical, Inc. (NASDAQ: ISRG), maker of the da Vinci® Surgical System.

Place a Purchase Order for this Report at:

“Growing acceptance of minimally invasive surgery and robotic surgery is because the robotic surgery provides an improvement over current surgical techniques. Open surgery is a difficult thing. Demand for less invasive procedures is coming as patients realize the benefits of quality of care from robotic surgery. Patients feel better after robotic surgery and the surgeries are more likely to be successful.”

The worldwide market for abdominal surgical robots at $2.7 billion in 2016 grows to $15.8 billion by 2023. The complete report provides a comprehensive analysis of abdominal surgical robots in different categories, illustrating the diversity of uses for devices in surgery. A complete procedure analysis is done, looking at numbers of procedures and doing penetration analysis.

Companies Profiled:

Market Leaders

• Intuitive Surgical

Market Participants

• AdEchoTech / T-MedRobotics /
• Auris Robotics
• Avra Robotics
• Cambridge Medical Robotics
• Chinese Surgical Robots
• Fosun Pharma
• Freehand
• Freehand 2010 / Prosurgics
• Google
• Johnson and Johnson / DePuy Synthes
• Medtronic / Mazor Robotics
• Medrobotics
• Medtronic
• Meerecompany / Eterne
• Smith & Nephew
• Stryker
• THINK Surgical
• Titan Medical
• TransEnterix
• Verb Surgical
• Virtual Incision
• Zimmer Biomet Acquires Medtech SA, Joins Surgical Robotics
• Selected Surgical Robot Companies

Key Topics

• Abdominal Surgical Robotics
• Surgical Robots
• Medical Devices
• Healthcare Robotics
• Surgical Enabling Technology
• Robotic-Assisted Minimally Invasive Surgery
• Robotic Surgical System
• Medical / Surgical Delivery Robots
• Surgical Assistive Technology
• Hospital Robots
• Robotic Surgery Equipment
• Surgical Robot Applications
• Next Generation Robotic Surgery
• Flexible Robot Platform,
• Minimally Invasive Surgery

Enquire more about the Report at:

Major Points Covered in Report:
1. Abdominal Surgical Robots Market Description And Market Dynamics
2. Abdominal Surgical Robot Market Shares And Forecasts
3. Surgical Robots Product Description
4. Abdominal Surgical Robot Technology And Research
5. Surgical Robots Company Description

Hector Costello
Orbis Research
+1 (214) 884-6817
email us here

Source: EIN Presswire

ArangoDB 3.2 Improves Scalability, Security and High Availability

ArangoDB 3.2 GA

New RocksDB Storage Engine, Distributed Graph Computing, Fault-Tolerant Foxx and Satellite Collections Open Up New Use Cases

This release is a major advancement, offering the community and clients key features to make ArangoDB their default database for new applications.”

— Claudius Weinberger, CEO and Co-Founder of ArangoDB

COLOGNE, GERMANY, July 20, 2017 / — ArangoDB, the makers of the leading native multi-model database, today announced that version 3.2 is Generally Available. This latest release expands ArangoDB to new use cases by being the most scalable, distributed multi-model and graph database.

“Some of the largest global companies are eager to adopt ArangoDB to simplify their architecture and improve developer productivity,” says Claudius Weinberger, CEO and Co-Founder of ArangoDB. “This release is a major advancement, offering the community and clients key features to make ArangoDB their default database for new applications.”

New Features & Improvements:
ArangoDB 3.2 is an important milestone in delivering on our pledge to improve productivity for every developer via native multi-model and includes:

Pluggable Storage Engine Architecture: The new architecture allows for multiple storage engines to be used, with Facebook’s RocksDB as its first. Even larger datasets can be stored, managed and processed efficiently with ArangoDB. RocksDB is ideal, in particular for write intensive applications.

Distributed Graph Computing: ArangoDB can now be used to gain high-level insights into hidden characteristics of graphs. Using the Pregel model, users can now work with common graph algorithms like PageRank, Community Detection, Vertex Centrality Measures and more.

Fault-Tolerant Foxx: ArangoDB’s rich JavaScript framework is widely used to build data-centric microservices and extend individually database functionalities. Now, with the new release, these Foxx services just received self-healing capabilities and can be leveraged in mission critical use cases.

Enterprise Features:
The Enterprise Edition builds upon our community version, adding some unique features for critical deployments:

Satellite Collections: Designed in cooperation with some of our largest customers, Satellite Collections enables faster join operations when working with sharded datasets and avoids expensive network hops during join processing among machines.

Encryption at Rest: Data stored on disk can now be encrypted with a secure AES algorithm. Even if a physical disk gets stolen, data will still be inaccessible. With this upgrade, ArangoDB takes another big step towards HIPPA compliance.

LDAP Integration: Centralized Authentication is common in Enterprises. ArangoDB can now be integrated with LDAP, allowing for an external authentication server to manage users.

Read the technical blog post for 3.2 (including tutorials):
Visit the ArangoDB Training Center:
Download ArangoDB 3.2:

About ArangoDB:
One database, one query language and three data models. With more than 1.4 million downloads, ArangoDB is the leading native multi-model database. It combines the power of graphs, with JSON documents and a key-value store. ArangoDB makes all of your data-models accessible with a single, elegant declarative query language.
ArangoDB is the simple, versatile and the performant answer to many challenges facing developers, start-ups and enterprises. Simplifying complexity and increasing productivity is the mission of ArangoDB GmbH, the company behind the project.

For more information, visit or follow us @ArangoDB

Jan Stuecke
ArangoDB GmbH
+49 (0) 221474415740
email us here

Max Neunhoeffer (Architect of ArangoDB) Interview at JOTB17

Source: EIN Presswire

Hospital Bed Market Growth Opportunities, Key Driving Factors, Market Scenario and Forecast to 2027

Global Hospital Bed Market Information by Usage (General, Birthing, Pediatrics and others), by Power (Electric, Semi Electric, and Manual),- Forecast to 2027

Major key Players include Hill-Rom Holdings,Getinge AB,Invacare,Linet spol,Paramount,Stryker,Gendron”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, July 20, 2017 / — Hospital Bed Global Market – Overview
According to the recent study report “Global Hospital Bed Market Research Report- Forecast to 2027” published by the Market Research Future, The global hospital bed market is expected to reach USD 5,291.8 million in the forecasted period and is expected to grow at as a CAGR of 4.4%.
Increase in healthcare expenditure by individuals and technological advancement is fueling the growth of the hospital bed market. Additionally, the increasing prevalence of chronic diseases and growth of aging population is contributing to the growth of the Hospital Bed market of globally. The increase in chronic diseases leads to an increase in the number of hospitalization cases, thus fueling the demand for hospital beds. However the key factor hampering the growth of the hospital bed market is its high cost. High cost of beds decreases the affordability of people in low income regions. Various hospital beds, such as electrical beds, birthing beds, bariatric beds, and critical care are extremely expensive, which makes them unaffordable for hospitals with limited budget allocated for healthcare. In the developing nations factors such as high cost and decreasing demand can act as a hurdle for this market, states the MRFR Research Analyst while commenting upon this deep diving study report, presented through more than 100 market data tables and figures, widely spread over 115 pages.

Request a Sample Copy @

Hospital Bed Global Market – Segments
The hospital bed market has been segmented in to 2 key dynamics for an enhanced understanding and convenience of the report.
Segmentation by Usage : Comprises – General, Birthing, Pediatrics and others
Segmentation On the basis of Power : Comprises – Electric, Semi Electric, and Manual
Among the various types, the general bed segment dominated the global market during the past few years holding a large market share.

Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Hospital Bed Market Research Report – Forecast to 2027"

Hospital Bed Global Market
Hospital beds contribute a great deal when it comes to fast recovery of the patient in the hospital or in home care for that matter. The hospital beds play a vital role in sector of health care. Improved circulation lead by better comfort & better positioning, and safety features bring ease in care giving. Each department in hospital caters the different types of patient with different healthcare requirements which results in the need of different kinds of medical supplies including different kinds of beds.
Hospital beds with power mattresses for uninterrupted pressure redistribution with fitted electric motor improve blood circulation and help preventing the formation of bed sores. The advanced features offered by these beds make them popular and leads to the growth of the market worldwide.
The global hospital bed market is expected to reach USD 5,291.8 million in the forecasted period and is expected to grow at as a CAGR of 4.4%.

Browse full report @

Key questions answered in this report
• What will the market size be in 2027 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.
Related Report

Global ADHD Therapeutics Information, by drug types (Stimulants and Non-stimulants), by distribution channels (hospitals, clinics, pharmacies, research laboratories and others) – Forecast to 2024.Know more about this report @

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here

Source: EIN Presswire

North America Pharmaceutical Logistics Market 2017 Analysis, Opportunities, Size, Trends, Growth and Forecast 2022

Wiseguyreports.Com Publish New Report On-“North America Pharmaceutical Logistics Market 2017 Analysis, Opportunities, Size, Trends, Growth and Forecast 2022”.

PUNE, INDIA, July 20, 2017 / —

Pharmaceutical Logistics Market in North America 2017

Executive Summary
Pharmaceutical Logistics is the logistics of pharmaceuticals, medical and surgical supplies, medical devices and equipment, and other products needed to support doctors, nurses, and other health and dental care providers. Because it’s final customers are responsible for the lives and health of their patients, medical logistics is unique in that it seeks to optimize effectiveness rather than efficiency. Medical logistics functions comprise an important part of the health care system: after staff costs, medical supplies are the single most expensive component of health care. To drive costs out of the health-care sector, medical logistics providers are adopting supply chain management theories.

Scope of the Report:
This report focuses on the Pharmaceutical Logistics in North America market, especially in United States, Canada and Mexico. This report categorizes the market based on manufacturers, countries, type and application.

Request a Sample Report @

Market Segment by Manufacturers, this report covers
Deutsche Post DHL
Kuehne + Nagel
UPS (Marken)
DB Group
Nippon Express
World Courier
SF Express
Kerry Logistics
CH Robinson
Air Canada Cargo

Market Segment by Countries, covering
United States

Market Segment by Type, covers

Market Segment by Applications, can be divided into

Complete Report Details @

Table of Contents
1 Market Overview
1.1 Pharmaceutical Logistics Introduction
1.2 Market Analysis by Type
1.2.1 Non-cold?Chain?Logistics
1.2.2 Cold?Chain?Logistics
1.3 Market Analysis by Applications
1.3.1 Bio?Pharma
1.3.2 Chemical?Pharma
1.3.3 Specially?Pharma
1.4 Market Analysis by Countries
1.4.1 United States Status and Prospect (2012-2022)
1.4.2 Mexico Status and Prospect (2012-2022)
1.4.3 Canada Status and Prospect (2012-2022)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force

2 Manufacturers Profiles
2.1 Deutsche Post DHL
2.1.1 Profile
2.1.2 Pharmaceutical Logistics Type and Applications Type 1 Type 2
2.1.3 Deutsche Post DHL Pharmaceutical Logistics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.4 Business Overview
2.1.5 Deutsche Post DHL News
2.2 Kuehne + Nagel
2.2.1 Profile
2.2.2 Pharmaceutical Logistics Type and Applications Type 1 Type 2
2.2.3 Kuehne + Nagel Pharmaceutical Logistics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.4 Business Overview
2.2.5 Kuehne + Nagel News
2.3 UPS (Marken)
2.3.1 Profile
2.3.2 Pharmaceutical Logistics Type and Applications Type 1 Type 2
2.3.3 UPS (Marken) Pharmaceutical Logistics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.4 Business Overview
2.3.5 UPS (Marken) News
2.4 DB Group
2.4.1 Profile
2.4.2 Pharmaceutical Logistics Type and Applications Type 1 Type 2
2.4.3 DB Group Pharmaceutical Logistics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.4 Business Overview
2.4.5 DB Group News
2.5 FedEx
2.5.1 Profile
2.5.2 Pharmaceutical Logistics Type and Applications Type 1 Type 2

For accessing accurate and deep understanding and to gain latest insights and key developments in the area of your interest, we also have a list of conferences in which you will be interested in, for more information, cordially check:

For updating knowledge or for thoroughly understanding various terminologies, we also have vast list of seminars for your reference, for more information cordially check:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EIN Presswire